Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Mitglied/er, Innere Klinik (Tumorforschung)
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
Keine vergangenen Veranstaltungen.
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Liver volumetry improves evaluation of treatment response to hepatic artery infusion chemotherapy in uveal melanoma patients with liver metastasesIn: Radiology and Oncology Jg. 58 (2024) Nr. 4, S. 509 - 516Online Volltext: dx.doi.org/ (Open Access)
-
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumoursIn: Nature (2024) 3801 in pressOnline Volltext: dx.doi.org/ (Open Access)
-
Prognostic value of clinical and radiomic parameters in patients with liver metastases from uveal melanomaIn: Pigment Cell and Melanoma Research Jg. 37 (2024) Nr. 6, S. 831 - 838Online Volltext: dx.doi.org/ (Open Access)
-
Tebentafusp in Patients with Metastatic Uveal Melanoma : A Real-Life Retrospective Multicenter StudyIn: Cancers Jg. 15 (2023) Nr. 13, 3430Online Volltext: dx.doi.org/ (Open Access)
-
Radiation Dose Aspects of Hepatic Artery Infusion Chemotherapy in Uveal Melanoma Patients with Liver MetastasesIn: Cardiovascular and Interventional Radiology Jg. 45 (2022) Nr. 6, S. 841 - 845Online Volltext: dx.doi.org/ (Open Access)
-
Early detection of metastatic uveal melanoma by the analysis of tumor-specific mutations in cell-free plasma DNAIn: Cancer Medicine Jg. 10 (2021) Nr. 17, S. 5974 - 5982Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Laktatdehydrogenase vor transarterieller hepatischer Chemoperfusion prognostiziert das Überleben und den Tumorprogress bei Patienten mit Lebermetastasen bei AderhautmelanomIn: RöFo: Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren Jg. 193 (2021) Nr. 06, S. 683 - 691Online Volltext: dx.doi.org/ (Open Access)
-
Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusionIn: Radiology and Oncology Jg. 55 (2021) Nr. 3, S. 347 - 353Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Improved survival in metastatic breast cancer : results from a 20-year study involving 1033 women treated at a single comprehensive cancer centerIn: Journal of Cancer Research and Clinical Oncology (2020)Online Volltext: dx.doi.org/ (Open Access)
-
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression : a phase 1 dose-escalation and dose-expansion studyIn: The Lancet Oncology Jg. 20 (2019) Nr. 10, S. 1454 - 1466Online Volltext: dx.doi.org/
-
A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancerIn: European Journal of Cancer (EJC) Jg. 100 (2018) S. 17 - 26Online Volltext: dx.doi.org/ (Open Access)
-
Konjunktivales Melanom : Standardisiertes Vorgehen in Diagnostik, Therapie und NachsorgeIn: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft Jg. 115 (2018) Nr. 6, S. 489 - 498Online Volltext: dx.doi.org/
-
A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors : Results from rogaratinib Phase-1 studyIn: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 5,
-
STREAM : A randomized discontinuation, blinded, placebo-controlled phase II study of sorafenib (5) treatment of chemonaive patients (pts) with metastatic uveal melanoma (MUM)In: Journal of Clinical Oncology (JCO) Jg. 35 (2017) Nr. 15, S. 9511Online Volltext: dx.doi.org/
-
A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumorsIn: Cancer Chemotherapy and Pharmacology Jg. 78 (2016) Nr. 2, S. 405 - 417Online Volltext: dx.doi.org/ (Open Access)
-
developmental therapeuticsPhase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levelsIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, 360O_PROnline Volltext: dx.doi.org/
-
A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer : a study of the CESAR Central European Society for Anticancer Drug Research-EWIVIn: European Journal of Cancer (EJC) Jg. 51 (2015) Nr. 1, S. 27 - 36Online Volltext: dx.doi.org/
-
A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanomaIn: Acta Radiologica Open Jg. 4 (2015) Nr. 4,Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphomaIn: Blood Jg. 126 (2015) Nr. 10, S. 1257 - 1258Online Volltext: dx.doi.org/
-
Overcoming the proliferation rate paradox : Clinical evaluation of a continuous dosing scheme of the novel oral Eg5 inhibitor 4SC-205In: Journal of Clinical Oncology (JCO) Jg. 33 (2015) Nr. 15_suppl, S. 2528Online Volltext: dx.doi.org/ Online Volltext
-
Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumoursIn: European Journal of Cancer (EJC) Jg. 51 (2015) Nr. 2, S. 146 - 156Online Volltext: dx.doi.org/
-
First-in-human study of 4SC-205 (AEGIS), a novel oral inhibitor of Eg5 kinesin spindle proteinIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 2564Online Volltext: dx.doi.org/
-
Phase lb study of BEZ235 plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC)In: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 621Online Volltext: dx.doi.org/
-
Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC)In: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15 Suppl., S. 627Online Volltext: dx.doi.org/
-
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumorsIn: Cancer Chemotherapy and Pharmacology Jg. 71 (2013) Nr. 1, S. 93 - 101Online Volltext: dx.doi.org/
-
A Phase i dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancerIn: Breast Cancer Research and Treatment Jg. 140 (2013) Nr. 2, S. 331 - 339Online Volltext: dx.doi.org/
-
Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer CenterIn: European Journal of Cancer (EJC) Jg. 49 (2013) Nr. 15, S. 3076 - 3082Online Volltext: dx.doi.org/
-
First-in-human phase i study of PRS-050 (Angiocal), an anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumorsIn: PLoS ONE Jg. 8 (2013) Nr. 12, S. e83232Online Volltext: dx.doi.org/ (Open Access)
-
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patientsIn: Breast Cancer Research and Treatment Jg. 142 (2013) Nr. 1, S. 81 - 88Online Volltext: dx.doi.org/
-
Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer : A study of the CESAR Central European Society for Anticancer Drug Research-EWIVIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 15 Suppl., S. 4035Online Volltext: dx.doi.org/
-
Regorafenib (BAY 73-4506) in advanced colorectal cancer : a phase I studyIn: British Journal of Cancer (BJC) Jg. 106 (2012) Nr. 11, S. 1722 - 1727Online Volltext: dx.doi.org/ (Open Access)
-
A clinical phase I study evaluating tolerability and pharmacokinetics (PK) of TriN 2755 in patients (pts) with advanced solid tumors : A study in cooperation with the Central European Society for Anticancer Drug Research (CESAR-EWIV)In: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 109 - 110
-
Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer : Results of a phase I studyIn: Journal of Clinical Oncology (JCO) Jg. 29 (2011) Nr. 15_suppl, S. 1092Online Volltext: dx.doi.org/
-
46 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - clinical efficacy and immunological results of a phase I studyIn: European Journal of Cancer / EJC Supplements Jg. 8 (2010) Nr. 7, S. 23 - 24Online Volltext: dx.doi.org/ (Open Access)
-
47 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - safety results of a clinical phase I studyIn: European Journal of Cancer / EJC Supplements Jg. 8 (2010) Nr. 7, S. 24Online Volltext: dx.doi.org/ (Open Access)
-
496 A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumoursIn: European Journal of Cancer / EJC Supplements Jg. 8 (2010) Nr. 7, S. 158 - 159Online Volltext: dx.doi.org/ (Open Access)
-
50 A phase I study of the safety, tolerability and pharmacokinetics of pazopanib (P) in combination with gemcitabine (G) for advanced solid tumorsIn: European Journal of Cancer / EJC Supplements Jg. 8 (2010) Nr. 7, S. 25Online Volltext: dx.doi.org/ (Open Access)
-
A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumorsIn: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. Suppl. 15, S. e13065Online Volltext: dx.doi.org/
-
Abstract P2-16-10: Combination of Tivozanib, an Oral Inhibitor of VEGFR, with Weekly Paclitaxel for Metastatic Breast Cancer : Preliminary Results of an Ongoing Phase 1 StudyIn: Cancer Research Jg. 70 (2010) Nr. 24, S. P2 - 16Online Volltext: dx.doi.org/
-
A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)
SITC 36th Anniversary Annual Meeting (SITC 2021), 10-14 November 2021, Washington & virtually,In: Journal for ImmunoTherapy of Cancer Jg. 9 (2021) Nr. Suppl. 2, S. A536 - A536Online Volltext: dx.doi.org/ (Open Access) -
Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathwayIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 15, S. 4513 - 4513Online Volltext: dx.doi.org/ (Open Access)
-
Rogaratinib in patients with advanced urothelial carcinomas selected for tumor FGFR mRNA expression and impact of mutations in the FGFR signaling pathway
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; Wien, 28. September - 2. Oktober 2018,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 321Online Volltext: dx.doi.org/ (Open Access) -
Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression.In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 6 Suppl., S. 494Online Volltext: dx.doi.org/ (Open Access)
-
Anti-tumor activity of the pan-FGFR inhibitor rogaratinib in patients with advanced urothelial carcinomas selected based on tumor FGFR mRNA expression levelsIn: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 5,
-
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patientsIn: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1: 31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie Berlin, 19.-22. Februar 2014: Abstracts, S. 19Online Volltext: dx.doi.org/ (Open Access)
-
Systemic treatment of metastatic uveal melanoma - a silver lining on the horizon?
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, 31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie Berlin, 19.-22. Februar 2014: Abstracts, S. 118 - 119Online Volltext: dx.doi.org/ -
WTZ-Tumorprofil-A preemptive biomarker profiling program in relation to personalized clinical drug development at a large German Comprehensive Cancer Center : Two years experience
31. Deutscher Krebskongress iKON - intelligente Konzepte in der Onkologie, 19.-22. Februar 2014, Berlin,In: Oncology Research and Treatment Jg. 37 (2014) Nr. Suppl. 1, S. 2 - 3Online Volltext: dx.doi.org/ -
Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastastic breast cancer patients
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Oncology Research and Treatment Jg. 36 (2013) Nr. Suppl. 7, S. 157Online Volltext: dx.doi.org/ -
An investigator-initiated monocentric phase I dose escalation trial of temsirolimus and irinotecan (TEMIR) in patients with relapsing glioblastoma multiforme (reGBM)
48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, 2012, Chicago, Ill., USA,In: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. 15, Suppl., 2086Online Volltext: dx.doi.org/ -
A phase I dose-escalation study with pharmacokinetics (PK) of TriN 2755 in patients with advanced solid tumors : A study in cooperation with the Central European Society for Anticancer Drug Research (CESAR-EWIV)In: Cancer Research Jg. 71 (2011) Nr. 8, Suppl., S. 1293Online Volltext: dx.doi.org/
-
A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumorsIn: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. 15 Suppl., S. 3011
-
Detection of new hepatic metastases in computed tomography (CT) with hepatic metastatic choroidal melanoma in Antiangiogenic Therapy - Progress or Pseudoprogression?
29. Deutscher Krebskongress. Berlin 24.-27. Februar 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 2, S. 188Online Volltext: dx.doi.org/ -
Evaluation of lesions density in computed tomography (CT) for assessment of tumor response in patients with hepatic metastatic choroidal melanoma under therapy with sorafenib
29. Deutscher Krebskongress. Berlin 24.-27. Februar 2010,In: Oncology Research and Treatment Jg. 33 (2010) Nr. Suppl. 2, S. 182Online Volltext: dx.doi.org/ -
Entwicklung eines Bestimmungsverfahrens für albumingebundenes Doxorubicin und pharmakokinetische Untersuchung in der MausDuisburg-Essen (2004) 96 Bl. : Ill., graph. Darst.
-
Register trial of sorafenib (S) for patients (pts) with metastatic uveal melanoma (metUvMel)
EORTC – NCI – ASCO Annual Meeting on ‘Molecular Markers in Cancer’, 27-29 October 2011, Brussels, Belgium,In: European Journal of Cancer (EJC) Jg. 47 (2011) Nr. Suppl. 4, S. S30Online Volltext: dx.doi.org/ -
Interpatient pharmacokinetic variability of 5-FU within metastatic and adjuvant colon cancer patients : First results from the West German Cancer Center
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 173Online Volltext: dx.doi.org/